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Summary 
This study examined the effects of chlorpromazine on the expression of CD81 in 
representative human cell lines of the central nervous system origin. 
Chlorpromazine is a neuroleptic that acts as a strong antagonist of dopamine 
receptors, which participate in processes like learning, memory, motivation, 
pleasure etc. Also, chlorpromazine affects many other membrane and cytosolic 
proteins, resulting in decreased communication between neurons and glial cells, 
especially astrocytes. Nevertheless, it has not yet been determined if 
chlorpromazine affects a specific form of intercellular communication that involves 
extracellular vesicles (EVs). EVs are membranous nanostructures that carry 
proteins, nucleic acids, lipids and other molecules. All types of cells release EVs 
and with them secretory cells can change the phenotype of recipient cells. The 
CD81 molecule is a member of the tetraspanin protein family ubiquitously 
expressed in all tissues, including the central nervous system. Next to the 
expression in plasma membrane, CD81 is present in intracellular membrane 
compartments and it is a recognized marker of EVs. In the nervous system, this 
protein is important for neuron-astrocyte interactions and is implicated in the 
response of astrocytes and microglia to trauma and disease.  
In this study, the human glioblastoma cell line U-87 MG and neuroblastoma SH-
SY5Y cells were treated with increasing concentrations of chlorpromazine (4, 8, 16 
and 32 µg/ml) for 24 hours. Flow cytometry analysis of the CD81 expression has 
shown that chlorpromazine affects the examined cell lines in different ways. U-87 
MG cells responded to chlorpromazine with a dose-dependent increase of CD81 
protein level, while SH-SY5Y cells showed decreased CD81 levels. These findings 
are the first to date that associate chlorpromazine with changes in CD81 
expression. Considering the role of this protein in neuron-astrocyte interactions 
and its presence in EVs, future studies are necessary to examine the effects of 
chlorpromazine treatment on processes important for intercellular communication 
in the nervous system. 
Key words: 
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Sažetak 
U ovom radu ispitan je utjecaj antipsihotika klorpromazina na izražaj proteina 
CD81 u humanim stanicama porijekla iz središnjeg živčanog sustava. Klorpromazin 
je neuroleptik koji djeluje kao snažan antagonist dopaminskih receptora, koji 
sudjeluju u procesima poput učenja, pamćenja, motivacije, užitka i dr. Povrh toga, 
klorpromazin utječe na mnoge druge membranske i citosolne proteine što rezultira 
smanjenom komunikacijom između neurona i glija stanica, prvenstveno astrocita. 
Međutim, dosad nije opisano utječe li klorpromazin i na specifičan oblik 
međustanične komunikacije koji uključuje izvanstanične vezikule (IV-e). IV-e su 
nanostrukture omeđene membranom koje sadrže proteine, nukleinske kiseline, 
lipide i druge molekule. Izlučuju ih sve vrste stanica i njima sekretorne stanice 
mogu utjecati na fenotip primateljskih stanica. CD81 je član obitelji tetraspanina, 
transmembranskih proteina izraženih u svim tkivima, pa tako i u stanicama 
središnjeg živčanog sustava. Osim na plazmatskim membranama, CD81 prisutan 
je i na citosolnim membranskim odjeljcima te je prepoznat kao marker 
izvanstaničnih vezikula. U živčanom je sustavu CD81 uključen u interakcije 
neurona i astrocita te u odgovor astrocita i mikroglija-stanica na ozljedu i bolest. 
U ovom radu stanične linije humanog glioblastoma (U-87 MG) i neuroblastoma 
(SH-SY5Y) tretirane su rastućim koncentracijama klorpromazina (4, 8, 16 i 32 
µg/ml) tijekom 24 sata. Analiza protočnom citometrijom pokazala je da 
klorpromazin ima oprečno djelovanje na razine CD81 u ispitanim staničnim 
linijama. U stanicama U-87 MG dolazi do dozno-ovisnog povećanja CD81, dok kod 
SH-SY5Y stanica razina ovog proteina opada s porastom koncentracije 
klorpromazina. Ova saznanja prvi put povezuju klorpromazin i promjene izražaja 
CD81. Imajući na umu brojne uloge CD81 u interakcijama neurona i astrocita te 
prisutnost tog proteina na izvanstaničnim vezikulama, buduća istraživanja trebala 
bi podrobnije ispitati posljedice ovih promjena na procese međustanične 
komunikacije u živčanom sustavu. 
Ključne riječi: klorpromazin, CD81, međustanična komunikacija, protočna 
citometrija 
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1. Introduction 
1.1. Cells of the central nervous system 
The human nervous system is a complex arrangement of tissues and cells 
specialized in communication. Anatomically, it can be divided into two main 
parts: the central nervous system (CNS) and the peripheral nervous system 
(PNS), as depicted in Figure 1 (3). The CNS consists of the brain and the 
spinal cord and it is protected by the skull and the spine (1). It functions as 
the central information processing and controlling unit of the entire body. 
The PNS is mainly comprised of peripheral nerves transmitting signals from 
all parts of the body to the brain and vice-versa. These nerves have cell 
bodies clustered in formations called ganglia. At the cellular level, the 
nervous system is composed of two major groups of neural cells: neurons 
and glial cells. The fundamental difference between the two lies in their 
electrical excitability– neurons can propagate electrical signals by 
generating action potentials, while glial cells are electrically non-excitable 
(1).  
Figure 1. Overview of the human nervous system (3) 
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Neurons are the primary signal-processing unit of the nervous system. 
These highly polarized cells consist of three major parts: the cell body 
(soma or perikaryon), dendrites, and axons, as seen in Figure 2 (2,3). The 
cell body and dendrites are receptive domains, while axons specialize in 
signal transmission. Information is passed between neurons by combining 
chemical and electrical signals at the synapses, structures discussed in 
greater detail further on.  
 
Figure 2. Structure of the neuron and the synapse (3) 
 
There are four major types of glial cells: oligodendrocytes, astrocytes, 
microglia and ependymal cells (1). Oligodendrocytes produce myelin 
sheaths that wrap around neuronal axons and enable rapid signal 
conduction. Astrocytes take up 20-50% of the volume of most brain areas. 
They have multiple roles, the most prominent being the control of ion and 
neurotransmitter homeostasis and synaptic plasticity, specifically the 
regulation of the formation, maintenance and removal of synapses (4). 
Astrocytes extend from blood vessels to neurons, transport ions and other 
molecules, and regulate the extracellular milieu (5). They produce many 
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growth factors that can affect the morphology, proliferation, differentiation 
and survival of specific neuronal subpopulations. In addition, astrocytes can 
undergo a process called reactive astrocytosis in response to injury and 
disease, resulting in the formation of a glial scar. Microglia are the tissue 
macrophages of the CNS, the mediators of the immune response (2). They 
scan for signs of damage in the brain with their multiple processes and can 
respond quickly and dramatically. Peripheral immune cells are restricted 
from accessing the CNS due to the blood-brain barrier (BBB). This unique 
structure is comprised of specialized endothelial cells that tightly regulate 
the interchange of ions, molecules and cells between the blood and the brain 
(6). Such regulation is critical for normal neuronal function because signal 
transduction across neurons depends on the ionic composition in and 
around them (2). On the other hand, hormones from the circulatory system 
can also act as neurotransmitters and interfere with synaptic transmission. 
Astrocytes, microglia and nerve terminals are closely associated with the 
endothelial cells that form the BBB, and they have supporting roles in 
barrier function. The final group of glia cells are ependymal cells which line 
the ventricles in the CNS, which are cavities that produce the cerebrospinal 
fluid (CSF). Ependymal cells regulate the production of the CSF, and form 
the blood-CSF barrier (7). An illustration of the four main types of glial cells 
is shown in Figure 3. 
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Figure 3. Illustration of different types of glial cells surrounding a neuron (8) 
 
In summary, neurons are the main signal-processing and transmitting cells 
in the CNS, yet their function is highly reliant on the surrounding 
oligodendrocytes, astrocytes and microglia. Much remains unknown about 
the various roles glial cells have in physiological and pathophysiological 
states. A growing number of studies aims to integrate knowledge about 
neurons and glial cells, emphasizing the importance of their 
interconnectedness in the functioning of the nervous system.  
 
1.2. Cell-to-cell communication in the CNS 
1.2.1. Neuronal communication 
Neuronal communication occurs at the synapse through a combination of 
chemical and electrical signals (9). Synapses are structures formed at the 
interface between axon terminals and target cells. Each synapse has a 
presynaptic element - the axon terminal, a synaptic cleft (approx. 20–50 
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µm wide), and a postsynaptic element - a dendrite, soma or another axon. 
Neurons receive information from other cells in the form of 
neurotransmitters, chemical signals that bind to specific receptors on target 
cells. The signal received by the postsynaptic neuron can be stimulatory or 
inhibitory, depending on the type of neurotransmitter released and its 
corresponding receptor. A neuron can simultaneously receive multiple 
impulses, both excitatory and inhibitory. These are processed in the cell 
body and cumulatively give rise to an electrical signal. In this way, the 
chemical information carried over by neurotransmitters translates into an 
electrical impulse which travels along axons. The diverse set of 
neurotransmitters in the CNS can be divided into: 1) small molecules such 
as glutamate, gamma-aminobutyric acid (GABA), glycine, acetylcholine, 
dopamine, serotonin, adenosine triphosphate (ATP) etc.; 2) neuropeptides 
such as endorphins; 3) lipid-based endocannabinoids; 4) gases such as 
nitric oxide, carbon monoxide etc. Glutamate and aspartate are the major 
excitatory neurotransmitters in the CNS, while GABA is the major inhibitory 
neurotransmitter in the brain.  
The propagation of electric impulses along the axon depends on the 
electrical potential on cell membranes (10). The inside of the plasma 
membrane has an electrical charge of -70 to -80 mV with respect to the 
outside, due to selective membrane permeability to ions and different ionic 
concentrations in the extracellular and the intracellular space. The surface 
of neurons contains many ion channels which open after receiving a signal, 
resulting in membrane depolarization. The influx of ions briefly reverses the 
membrane resting potential to positive on the inside of the cell. This triggers 
the opening of more ion channels along the membrane and results in a 
depolarization wave, termed the action potential. The resulting electrical 
signal then travels from the initial segment of the axon (axon hillock) to the 
axon terminal (2). When the action potential reaches the axon terminal, it 
leads to an increase in intracellular calcium levels. This causes the fusion of 
neurotransmitter-filled synaptic vesicles with the plasma membrane and the 
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release of their content into the synaptic cleft. Once there, the 
neurotransmitters can cross the synaptic gap and bind to receptors on the 
membrane of the post-synaptic neuron, thereby completing the neuron-to-
neuron signal transmission. 
 
1.2.2. Astrocytic signalling 
Glial cells have historically been considered as passive support to neurons, 
a position that has changed with the advancement of research methods (1). 
Based on the observed communication between astrocytes and neurons at 
the synapse, this view has been replaced with the notion that glial cells 
actively participate in information processing in the brain. A single astrocyte 
makes contact with a large number of neurons at a structure called the 
tripartite synapse. The function of these contacts is to regulate synaptic 
transmission by exchanging information with the synaptic neurons. 
Moreover, these intercellular interactions at the tripartite synapse have 
been implicated in the regulation of synaptic plasticity, the ability of the 
synapses to strengthen or weaken in accordance with neural activity (11). 
Astrocytes express neurotransmitter receptors and can register neuronal 
activity through them (1). They respond by increasing intracellular calcium 
levels and releasing gliotransmitters: excitatory and inhibitory amino acids 
like glutamate, aspartate, GABA and glycine; ATP, eicosanoids and 
prostaglandins, neuropeptides, neurotrophins and a range of cytokines. The 
gliotransmitters can bind to extrasynaptic receptors on both the presynaptic 
and postsynaptic neurons and modulate their activity (11).  
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1.2.3. Extracellular vesicles as mediators of intercellular 
communication  
Cell-to-cell communication in the CNS is more diverse than the most well-
known neuron-to-neuron signalling. Emerging studies are uncovering 
complex interactions between multiple cell types and mechanisms of 
information exchange in the brain. One newly proposed mechanism of cell-
to-cell communication takes place via membranous vesicles they secrete 
(12). Extracellular vesicles are membranous nanostructures produced by 
almost all types of cells and present in all bodily fluids, including the 
cerebrospinal fluid. They encapsulate proteins, lipids and nucleic acids in a 
phospholipid bilayer. Initially, cells were thought to release EVs to dispose 
of unneeded or harmful content, but accumulating evidence points to their 
important role in cell-to-cell communication (13). EV cargo serves as a 
functional messenger involved in cellular division, survival, differentiation, 
response to stress and apoptosis, and can lead to a change in the phenotype 
of the recipient cell. As such, EVs are involved in physiological as well as 
pathophysiological processes and could hence serve as potential diagnostic 
and therapeutic targets (14). 
Based on their biogenesis and size, EVs can be divided into exosomes, 
microvesicles and apoptotic bodies. Exosomes are reported to be between 
30 nm and 100 nm in diameter, and carry specific subsets of proteins on 
their surface, including the tetraspanin cluster of differentiation 63 (CD63) 
and CD81 (15). They are generated by the endosomal system via endocytic 
pathways, as seen in Figure 4 (16). The intracellular precursor organelles 
of exosomes are called multivesicular bodies (MVBs). MVBs undergo 
membrane invagination resulting in the formation of intraluminal vesicles 
(ILVs). This MVB complex gets trafficked to the plasma membrane, and its 
subsequent fusion results in the secretion of ILVs in the form of exosomes. 
Microvesicles (100 nm to 1 µm) are reported to emerge via direct budding 
from the plasma membrane (13). They are more heterogenous than 
exosomes with respect to surface markers, and there is no known specific 
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marker defining them. Finally, apoptotic bodies or blebs are produced by 
cells undergoing apoptosis and range from 1 µm to > 2 µm in diameter. 
They can be identified via DNA and histone detection. Although the terms 
“exosomes” and “microvesicles” are commonly used throughout literature, 
it is now commonly accepted that there is much greater heterogeneity 
within these subgroups with no clear markers to distinguish them. The 
umbrella term “extracellular vesicles” (EVs) is recommended to avoid 
confusion.  
 
 
Figure 4. Illustration of EV formation, secretion and uptake. MVB = multivesicular body; 
ILVs = intraluminal vesicles (16)  
 
The basis of intercellular communication via EVs is accomplished by two 
main mechanisms: 1) specific ligand-receptor interactions, and 2) vesicle 
cargo uptake into target cells through membrane fusion or vesicle 
internalization (18). Multiple studies point to endocytosis as the primary 
internalization mechanism, based on reduced EV uptake when cells are 
treated with endocytosis inhibitors. Nevertheless, conflicting evidence 
might suggest that EV uptake happens through multiple mechanisms, 
depending on the cell of origin, type of EVs and characteristics of the 
recipient cells.  
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1.2.4. Extracellular vesicles in the nervous system 
Almost all cell types in the brain release EVs: neural stem/progenitor cells, 
neurons, astrocytes, oligodendrocytes and microglia (12). EVs are 
implicated in processes ranging from neural development, synaptic 
strength, plasticity and nerve regeneration to inflammation, 
neurodegeneration and other pathological processes. Recent studies cite 
the biomarker potential of EVs in a number of brain disorders, such as 
Alzheimer’s disease or glioblastoma (12,16). 
Exosome release from neurons reportedly depends on synaptic activity as 
they are shed upon depolarization and selectively bind to other neurons, 
suggesting involvement in neuron-to-neuron communication (12). Neuronal 
EVs are enriched with proteins related to synaptic plasticity and with 
activity-related miRNAs. EVs also facilitate the elimination of inappropriate 
synaptic connections which is important for the reorganization of neuronal 
circuits in the brain in physiological, as well as injury-related states. EVs in 
the brain are implicated in deleterious processes such as various 
neurodegenerative diseases, glioblastoma and inflammation. During brain 
injury, astrocytes in the injured tissue release ATP (excitatory 
neurotransmitter), and high levels of extracellular ATP induce microglia to 
release EVs carrying interleukin (IL)-1β, a key initiator of the acute 
inflammatory response (14). Astrocytes of the blood-brain barrier also 
respond to neuronal injury by releasing IL-1β enriched EVs, exacerbating 
tissue deterioration.  
 
1.3. Tetraspanin proteins  
1.3.1. General characteristics of tetraspanins 
Tetraspanins are a superfamily of proteins also known as the 
transmembrane 4 superfamily (TM4SF), due to their characteristic four 
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hydrophobic domains that traverse cellular membranes (19). These 
proteins have two extracellular loops, one smaller (SEL or EC1) and one 
larger (LEL or EC2), with two short intracellular N- and C-terminal domains, 
as represented in Figure 5 on the example of CD81. They participate in 
various cellular functions, including adhesion, migration, signalling and 
pathogen infection (20). The tetraspanins are thought to be implicated in 
multi-molecular signal transduction complexes on the cell membrane. 
 
Figure 5. Schematic representation of CD81. Four transmembrane domains are 
characteristic for the tetraspanin family of proteins. CD81 has one small extracellular loop 
(SEL) and one large extracellular loop (LEL) (21) 
 
Tetraspanins are abundantly expressed in the nervous system, and recent 
studies focus on their roles at the synapse (19). The tetraspanin interactions 
in the CNS currently being studied include the regulation of glutamatergic 
and dopaminergic signalling, receptor trafficking and other processes 
important in synaptic transmission and plasticity. For example, Tspan7 was 
found to form a part of a complex with the D2 dopamine receptor in the 
soma and along the neurites of neurons, and its silencing has led to 
upregulation of the surface D2 receptor (22).  
Tetraspanins have been shown to associate with different partner proteins 
to form tetraspanin-enriched microdomains (TEMs) (19). One variant of 
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such partner proteins are integrins, cell adhesion molecules important in 
cell-cell or cell-extracellular matrix interactions, which points to the 
implication of tetraspanins in intercellular contacts and communication. 
Tetraspanin microdomains seem to participate in vesicular and cellular 
fusion, including EV-cell binding. The tetraspanins CD63, CD9 and CD81 are 
highly abundant on EVs. CD63 appears to be important for the biogenesis 
of lysosome-related organelles (23). CD9 knockout mice leads to defective 
exosome secretion in bone marrow dendritic cells (24), and treating 
dendritic cells with antibodies against CD81 or CD9 has led to a reduction 
in EV uptake (20). These and other studies point to the possible involvement 
of tetraspanins in EV trafficking.  
 
1.3.2. The tetraspanin CD81 
CD81 is also known as Target of the Antiproliferative Antibody 1 (TAPA-1) 
(25). This protein was found to be involved in a wide range of biological 
activities including cellular activation, proliferation, differentiation, cell-cell 
fusion, and adhesion). It is also implicated in infection by many pathogens. 
Its expression in humans is ubiquitous in many cell types, including 
neuronal and glial cells. CD81 is recognized as a marker of exosomes and 
is enriched on MVBs, their precursor organelles (26). The crystal structure 
of CD81 was recently published, revealing a specific cholesterol-binding site 
also observed in vitro (27). When cholesterol is not bound to CD81, this 
protein can more readily adopt an “open” conformation, and possibly favour 
binding to partner proteins. These speculations suggest a modulating role 
of cholesterol in CD81 function. 
CD81 plays an important mediating role in neuron-astrocyte interactions 
and astrocyte reactivity. Astrocytes can re-enter the cell cycle, especially in 
response to trauma and disease. In homeostasis, the number of astrocytes 
remains mostly unchanged throughout life. This was proven to result from 
their direct contact with neurons (28). Specifically, CD81 was shown to be 
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a critical regulator of astrocytic proliferative arrest induced by neurons. This 
proliferative arrest is a process in which cells permanently leave the cell 
cycle and reach terminal differentiation. It is crucial for establishing and 
maintaining a proper ratio of cell types in the central nervous system. In a 
separate study, it was demonstrated that CD81-null mice have significantly 
enlarged brains compared to wildtypes (30% increase) as a result of an 
increased number of astrocytes and microglia, but not neurons (29). Also, 
when targeted with anti-CD81 antibodies, cultured rat astrocyte 
proliferation was strongly inhibited (25). Studies in rats have shown that 
after traumatic injury to the CNS, CD81 expression is increased in reactive 
astrocytes and microglia (30). These and other studies support the 
hypothesis that CD81 participates in cell-to-cell communication in the CNS 
and that its expression undergoes changes upon injury. 
 
1.4. Antipsychotics  
Antipsychotic drugs are generally classified into two major groups: the 
typical and atypical antipsychotics (31). Chlorpromazine and its derivates 
belong to a group of first generation or typical antipsychotics that exert 
their action mainly by targeting dopamine D2 receptors. Many other 
antipsychotics and antidepressants were developed owing to that major 
discovery. Furthermore, typical antipsychotics were shown to inhibit EV 
uptake in vitro (32). The second generation, atypical antipsychotics are 
derived from clozapine and act as strong D2 and serotonin 2A receptor 
antagonists. Some atypical antipsychotic drugs affect tetraspanin 
expression in vivo (33). Both typical and atypical antipsychotics have been 
shown to disrupt the intracellular cholesterol trafficking, resulting in the 
accumulation of lipids in the late endosome/lysosome compartment (34).  
13 
 
 
 
Chlorpromazine is a dimethylamine derivative of phenothiazine – 10-(3-
dimethylaminopropyl)-2-chlorphenothiazine, shown in Figure 6 (35). It is 
indicated for the treatment of schizophrenia, the manic manifestations of 
manic-depressive disorder, as pre-surgery relief for restlessness and 
anxiety, to control nausea and vomiting, for acute intermittent porphyria, 
for relief of intractable hiccups and as an adjunct in the treatment of 
tetanus. Its success in the therapy of schizophrenia is attributed to 
antagonistic action on the dopamine receptors of neurons. It blocks 
postsynaptic D1, D2, D3 and D4 subtypes of dopaminergic receptors (36). It 
also acts on serotonin receptors 5-HT1 and 5-HT2 with anxiolytic and anti-
depressive effects. The combined effect of blocking D2, histamine H1 and 
muscarinic M1 receptors result in reduced nausea and vomiting.  Multiple 
studies show that chlorpromazine binds to several other proteins like 
calmodulin (CaM – intracellular Ca2+ receptor  implicated in Ca2+-mediated 
regulation of gene expression), certain channel proteins, DNA 
topoisomerase, K-Ras and other membrane proteins (37). Among other 
effects, it has been shown that chlorpromazine can affect endocytosis and 
inhibit internalisation of exosomes (38).  
Chlorpromazine has varied effects in neuronal and glial cells. It was shown 
to exert cytotoxic effects in neuroblastoma cell lines IMR-32 and SH-SY5Y  
(39). It was also demonstrated to negatively affect the viability of 
Figure 6. Structure of chlorpromazine. Created with 
ChemDoodle 8.0.0.3b and Adobe Illustrator CC 2015 
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glioblastoma cells as well, specifically the U-87 MG cell line (37). Treatment 
with this antipsychotic reduced intercellular communication via gap 
junctions in mammalian neurons and astrocytes in vitro (40). Furthermore, 
a study in rats treated with chlorpromazine demonstrated a significant 
decrease in axosomatic synapses on neurons in the hypothalamus 
accompanied by an increase in astrocytic processes (41). These studies 
imply that chlorpromazine has a currently unexplained influence on basic 
aspects of cell-to-cell communication in the CNS. Despite almost 70 years 
of research into chlorpromazine mechanisms of action, much remains 
unknown and deserves more attention, especially considering the variety of 
molecular targets it affects.  
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2. Aim of the study 
The aim of this study is to examine possible changes of CD81 expression in 
neural cells upon chlorpromazine treatment. The tetraspanin CD81 is 
present on plasma and intracellular membranes of cells and enriched on 
multivesicular bodies that give rise to exosomes. This protein is implicated 
in neuron-astrocyte interactions and upregulated in glial cells in response 
to injury. These findings suggest CD81 involvement in intercellular 
communication in the CNS. Chlorpromazine has a cytotoxic effect on human 
cell lines representative for neurons and glia, and it affects cell-to-cell 
communication with poorly understood underlying mechanisms. No 
research to date has described the effect of chlorpromazine on tetraspanin 
expression. 
The chlorpromazine effect will be studied on two neural cell lines: U-87 MG 
cell line as a representation of glial cells and SH-SY5Y as a model for 
neurons. The specific objectives of this study are: 
1) to determine cell viability of neural cell lines after exposure to increasing 
concentrations of chlorpromazine for 24 hours; 
2) to examine the effect of different concentrations of chlorpromazine on 
CD81 protein levels in neural cells by flow cytometry; 
3) to compare cellular responses to chlorpromazine and identify cells in 
which CD81 might be involved in intercellular communication. 
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3. Materials and Methods  
 
3.1. Chemicals 
Dulbecco’s modified Eagle’s medium (DMEM), PAN-Biotech, Aidenbach, 
Germany 
Fetal calf serum (FCS), PAN-Biotech, Aidenbach, Germany 
Saponin, Carl Roth, Karlsruhe, Germany 
Chlorpromazine hydrochloride, Sigma Aldrich, St. Louis, USA 
Ethanol, Carl Roth, Karlsruhe, Germany  
Newborn calf serum (NBC) PAN-Biotech, Aidenbach, Germany 
Potassium chloride (KCl), Carl Roth, Karlsruhe, Germany 
Potassium dihydrogen phosphate (KH2PO4), Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl), Carl Roth, Karlsruhe, Germany 
Disodium phosphate (Na2HPO4), Carl Roth, Karlsruhe, Germany 
Ethylenediaminetetraacetic acid disodium salt (Na2EDTA), Carl Roth, 
Karlsruhe, Germany 
Sodium azide (NaN3), Carl Roth, Karlsruhe, Germany 
 
3.2. Solutions and buffers 
BD Cytofix/CytopermTM Fixation and Permeabilization solution, BD 
Biosciences, Franklin Lake, USA 
Chlorpromazine hydrochloride in ethanol, 1 mg/ml 
Complete 10% cell culture medium DMEM: DMEM, FCS 10% (w/v), 2mM L-
glutamine, penicillin-streptomycin 1000 i.u./ml, 0.11 mg/ml pyruvate  
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GibcoTM MEM Non-Essential Amino Acids 100x, Thermo Fisher Scientific, 
Waltham, USA 
L-Glutamine, Powder, PAN-Biotech, Aidenbach, Germany  
Penicillin-Streptomycin 10,000 U/ml Penicillin, 10 mg/ml Streptomycin, 
PAN-Biotech, Aidenbach, Germany 
Phosphate-buffered saline (PBS), PAN-Biotech, Aidenbach, Germany 
Saponin buffer: 1% saponin, 0,95 mM sodium azide (NaN3), 1,9% NBC, 1x 
PBS 
Sodium Pyruvate 100 mM, PAN-Biotech, Aidenbach, Germany 
Trypsin-EDTA, Sigma-Aldrich, St. Louis, USA 
Trypan Blue Solution 0,4% in PBS, Mediatech, Inc, Manassas, USA 
Permeabilization Buffer 10X, eBioscienceTM Thermo Fisher Scientific, 
Waltham, Massachusetts, USA 
Flow cytometry buffer 1x: 0.15 M NaCl, 2 mM KH2PO4, 17 mM Na2HPO4, 4 
mM KCl, 1 mM Na2EDTA, 2 mM NaN3 
 
3.3. Antibodies 
Primary antibody: polyclonal rabbit anti-human CD81, Biorbyt, San 
Francisco, USA  
Secondary antibody: anti-rabbit Alexa Fluor-488, Molecular Probes, Thermo 
Fisher, Waltham, Massachusetts, USA  
 
3.4. Cell lines 
The U-87 MG glioblastoma cell line (ATCC HTB-14) was kindly provided by 
Hrvoje Šimić, PhD (Department of Neurosurgery, Faculty of Medicine, 
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University of Rijeka, Croatia). U-87 MG cells are epithelial-like adherent 
cells derived from brain tissue of a human male glioblastoma patient.  
The SH-SY5Y neuroblastoma cells (ATCC CRL-2266) were kindly provided 
by Željko Svedružić, PhD (Department of Biotechnology, University of 
Rijeka, Croatia). This cell line is a subline of the neuroblastoma SK-N-SH 
cell line, established in 1970 from human bone marrow of a female patient 
with metastatic bone tumour. It is comprised of epithelial-like adherent and 
suspended cells.  
 
3.5. Methods 
3.5.1. Cell maintenance 
U-87 MG cells were cultured in cell culture dishes (100 mm in diameter, 
Greiner, Frichenhausen, Germany) in a complete 10% DMEM medium and 
0.1 µg/ml of non-essential amino acids (Thermo Fisher Scientific, Waltham, 
USA). SH-SY5Y were cultured in plastic flasks (surface area 25 cm2, Greiner, 
Frichenhausen, Germany) in a complete 10% DMEM cell culture medium. 
Cells were incubated at 37°C in a humidified atmosphere containing 5% 
CO2. 
The U-87 MG and SH-SY5Y cells were detached from the culturing dish/flask 
with trypsin-EDTA pre-warmed to 37°C, applied for 3 minutes or until visibly 
detached. The action of trypsin was blocked with pre-warmed complete 
10% DMEM and the resuspended cells were transferred into FACS tubes 
(BD Biosciences, Franklin Lakes, New Jersey, USA).  
 
3.5.2. Chlorpromazine treatment of U-87MG and SH-SY5Y cells  
Cells were detached from the culturing dish/flask by trypsin-EDTA as 
described above. After centrifugation at 1800 rpm for 5 min at 20°C, cells 
were resuspended in 5 ml of fresh complete 10% DMEM. Cells were counted 
in the Neubauer chamber (Marienfeld, Lauda-Königshofen, Germany) as 
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described in 3.5.3. and transferred to 6-well tissue culture plates (Greiner, 
Frichenhausen, Germany) at concentration of 500,000 cells per well. The 
cells were incubated for 24 hours at 37°C in a humidified atmosphere 
containing 5% CO2. 
Prior to chlorpromazine treatment, the cell culture media was aspirated 
from the cells cultured on 6-well plates. The first set of cells was treated in 
duplicate with 16 and 32 µg/ml of chlorpromazine in fresh 10% DMEM. Non-
essential amino acids were added to the media of U-87 MG cell line (0.1 
µg/ml). The second set of cells was treated with lower concentrations of 
chlorpromazine (4, 8 and 16 µg/ml) for 24 hours in triplicate. This 
experiment was performed with approx. 500,000 cells per well for U-87 MG 
and 330,000 of SH-SY5Y cells per well. 
 
3.5.3. Cell viability assessment 
After 24 hours of chlorpromazine treatment, the cells were detached from 
the surface of the wells with trypsin, resuspended in 1 ml PBS and 
transferred to FACS vials (BD Biosciences, Franklin Lakes, New Jersey, 
USA). 
Aliquots of 25 µl of cell suspensions in PBS were stained with 100 µl trypan 
blue. This dye can only enter dead cells which have compromised 
membrane integrity, while live cells remain unstained. Both live and dead 
cell count was performed in the Neubauer chamber (Figure 7). Their viability 
was estimated as the ratio of live cells to total number of cells (live and 
dead). 
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Figure 7. A) Neubauer chamber used for cell viability assessment; B) gridline indicating 
one of the sets of 16 squares used for counting cells42 
 
The number of cells was calculated based on the following formula:  
𝑁 =
𝑛
4
× 𝑓 × 104 × 𝑉 
N = calculated number of cells in a volume (V) 
n = cells counted in 4 sets of 16 squares of the gridline, shown in Figure 
7B  
f = dilution factor; f = 5 
 
3.5.4. Flow cytometry 
After determining the cell count and viability in response to chlorpromazine 
treatment, the cells were fixed and permeabilized with Cytofix/Cytoperm 
Fixation and Permeabilization buffer for 20 minutes in order to examine both 
surface and intercellular expression of CD81. The cells were then rinsed with 
saponin buffer and centrifuged (2000 rpm, 2 min, 4°C). Cell pellets were 
resuspended in 300 µl saponin buffer, vortexed and divided into 3 FACS 
vials (100 µl of cell suspension per vial). This was followed by the staining 
procedure: negative control - no staining; control with the secondary 
antibody only (anti-rabbit Alexa Fluor 488, 8 µg/ml; 30 min, 4°C); double-
stained - primary (anti-CD81; 1:50; 60 min, 4°C) and secondary antibody 
(anti-rabbit Alexa Fluor 488, 8 µg/ml; 30 min, 4°C). After each staining 
step, the cells were rinsed with saponin buffer and centrifuged (2000 rpm, 
2 min, 4°C). Finally, cell pellets were resuspended in a 500 µl flow 
cytometry buffer and subjected to flow cytometry analysis (Beckton 
A B 
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Dickinson FACScalibur, BD Biosciences, Franklin Lakes, New Jersey, USA). 
Flow cytometry settings were optimized for the analysis of CD81 expression 
in U-87 and SH-SY5Y cells as seen in Figure 8. The analysis was performed 
until 10,000 cells were detected in the gated area. The FL-1 channel was 
used to measure the fluorescence intensity of the Alexa Fluor 488 
fluorochrome, later used in the FlowJo software (FlowJo, Ashland, USA) to 
determine the mean fluorescence intensity (MFI).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Flow cytometry settings used for the analysis of CD81 expression in U-87 MG (A) 
and SH-SY5Y cells (B) upon treatment with different concentrations of chlorpromazine.  
 
3.5.5. Data annotation and statistical analysis  
Data annotation was performed in Microsoft Excel 2019 (Microsoft 
Corporation, Redmond, USA). The results obtained by flow cytometry were 
checked for sample quality, graphically presented and analysed using 
FlowJo 10 software (FlowJo, Ashland, USA).  MFI values of cells stained only 
with the secondary antibody were subtracted from the MFI of cells stained 
with both the primary and secondary antibody to obtain the final MFI value 
of anti-CD81+Alexa Fluor 488. A statistical analysis with graphical 
A 
B 
22 
 
presentation of the results was performed in GraphPad Prism 7 (GraphPad 
Software, Inc., La Jolla, USA). After testing for data distribution with the 
Shapiro-Wilk test, parametric or nonparametric tests were used. Data with 
normal distribution were further analysed with parametric tests, while data 
which did not show normal distribution were tested by nonparametric tests. 
To compare the effect of growing concentrations of chlorpromazine, ANOVA 
repeated measures analysis or the Friedman test was used with respective 
post-hoc analysis (Student’s T test for dependent samples or Wilcoxon 
test), in accordance with data distribution. A difference of p<0.05 was 
considered significant. 
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4. Results 
 
4.1. SH-SY5Y cells are more susceptible to chlorpromazine toxicity 
than U-87 MG cells 
 
The aim of this study was to examine the effect of chlorpromazine on the 
levels of CD81 protein in U-87 MG and SH-SY5Y cells. To determine the 
effective concentration range, the cells were exposed to increasing 
concentrations of chlorpromazine (4, 8, 16 and 32 µg/ml), and their viability 
was assessed by trypan blue staining technique after 24 hours of 
chlorpromazine treatment. The results represented in Figure 9A show that 
the highest applied concentration (32 µg/ml) significantly decreased U-87 
MG cell viability to 60 ± 14.5% in comparison to untreated cells (82 ± 
23%). The viability of U-87 MG cells treated with 4, 8 and 16 µg/ml was at 
89 ± 5%, 86 ± 9% and 91 ± 6%, respectively, with no statistically 
significant difference relative to untreated cells. 
The viability of SH-SY5Y cells treated with 4, 8 and 16 µg/ml of 
chlorpromazine is shown in Figure 9B and it was at 62 ± 10%, 87 ± 12% 
and 75 ± 8%, respectively, with no statistically significant difference in 
comparison to untreated cells (74 ± 16%). Chlorpromazine concentration 
of 32 µg/ml resulted in no observed viable SH-SY5Y cells. 
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Figure 9. Chlorpromazine significantly affects U-87 MG and SH-SY5Y cell viability 
at the concentration of 32 µg/ml. U-87 MG glioblastoma cells (A) and SH-SY5Y 
neuroblastoma cells (B) were treated with depicted concentrations of chlorpromazine for 
24 hours. Cell viability was determined by trypan blue staining and expressed as the 
number of live cells relative to the total number of cells (live + dead). Shown are mean 
values of cell viability from 2 experiments performed either in duplicates or triplicates with 
the total number of samples as quintuplicate (0 and 16 µg/ml), triplicate (4-8 µg/ml) or 
duplicate (32 µg/ml). Standard deviations are depicted as vertical lines. * p≤0.05 and ** 
p≤0.01. 
 
 
 
 
 
 
 
 
A 
B 
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4.2. Chlorpromazine treatment increases CD81 protein level in U-
87 MG cells 
 
Given that U-87 MG cells treated with increasing concentrations of 
chlorpromazine presented good viability, their CD81 protein levels were 
examined by flow cytometry in the following step. All flow cytometric 
analyses of anti-CD81 fluorescence in U-87 MG untreated and 
chlorpromazine treated cells were made on cells pertinent to the gate 
excluding cellular debris (Figure 10A). Figure 10B shows a representative 
dot plot of the forward scatter (FSC) parameter and fluorescence of cells 
treated with 32 µg/ml of chlorpromazine. A histogram depicting an overlay 
of fluorescence in cells treated with 0, 16 and 32 µg/ml shows that the 
highest applied concentration of chlorpromazine (32 µg/ml) induced a 
visible increase in anti-CD81 fluorescence compared to untreated cells 
(Figure 10C). Statistical analysis of mean MFI values shown in Figure 10D 
confirmed that treatment of U-87 MG cells with 32 µg/ml of chlorpromazine 
leads to a significant increase in anti-CD81 fluorescence relative to 
untreated cells (MFI0 = 326,2 ± 53,0; MFI32 = 728,2 ± 18,0). Applied 
concentrations of 4, 8 and 16 µg/ml chlorpromazine did not produce a 
statistically significant change in MFI values compared to untreated cells, 
yet there was a significant difference of MFI at 4 compared to 32 µg/ml  
(MFI4 = 336,5 ± 114,2; MFI8 = 300,6 ± 87,9; MFI16 = 365,7 ± 78,6). 
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Figure 10. Chlorpromazine treatment increases CD81 protein level in U-87 MG cells 
at the concentration of 32 µg/ml. Cells treated with different concentrations of 
chlorpromazine (0, 4, 8, 16 and 32 µg/ml) for 24 hours were stained with anti-CD81+Alexa 
Fluor-488 and subjected to flow cytometry; A) Representative forward (FSC) and side 
scatter (SSC) diagram of untreated cells used for gating; B) Representative dot plot 
showing FSC and fluorescence of cells treated with 32 µg/ml of chlorpromazine. C) 
Representative histogram showing fluorescence of U-87 MG cells treated with indicated 
chlorpromazine concentrations. D) Mean Fluorescence Intensity (MFI) values of anti-CD81 
+ Alexa-488 treated with growing concentrations of chlorpromazine (0, 4, 8, 16 and 32 
µg/ml), obtained as average values of 2 experiments performed either in duplicates or 
triplicates with the total number of samples as quintuplicate (0 and 16 µg/ml), triplicate 
(4-8 µg/ml) or duplicate (32 µg/ml). Standard deviations are depicted as vertical lines.       
* = statistical significance p≤0.05. 
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4.3. Chlorpromazine treatment decreases the expression of CD81 
in SH-SY5Y cells  
 
After assessing SH-SY5Y cell viability in response to increasing 
chlorpromazine concentrations (4, 8, 16 and 32 µg/ml), all samples were 
subjected to flow cytometry analysis of CD81 levels, even though the 
concentration of 32 µg/ml of chlorpromazine showed pronounced 
cytotoxicity in this cell type. Figure 11A shows the gate set on untreated 
cells and used in all further flow cytometric analysis of anti-CD81 
fluorescence in SH-SY5Y cells. Figure 11B shows a representative dot plot 
of the forward scatter (FSC) parameter and fluorescence of cells treated 
with 16 µg/ml of chlorpromazine. A representative histogram overlay of 
anti-CD81 fluorescence illustrates a visible, yet limited decrease of 
fluorescence in cells treated with 4, 8 and 16 µg/ml of chlorpromazine 
compared do untreated control (Figure 11C). Statistical analysis of the 
obtained results shows a significant decrease in MFI values of CD81 in SH-
SY5Y cells treated with 8 µg/ml of chlorpromazine compared to cells treated 
with 4 µg/ml (MFI4 = 197,7 ± 87,9M MFI8 = 125,4 ± 75,8) (Figure 11D). 
There is a distinct difference in the MFI of cells treated with 8 and 16 µg/ml 
of chlorpromazine relative to untreated control (MFI0 = 191,4 ± 82,1; MFI8 
= 125,4 ± 75,8; MFI16 = 100,98 ± 24,8) and a pronounced decrease in the 
MFI of cells treated with 32 µg/ml of chlorpromazine (MFI32 = 12,05 ± 0,9), 
yet statistical significance was not met.  
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Figure 11. Chlorpromazine decreases CD81 expression in SH-SY5Y cells at the 
concentration of 32 µg/ml. Cells treated with different concentrations of chlorpromazine 
(0, 4, 8, 16 and 32 µg/ml) for 24 hours were stained with anti-CD81+Alexa Fluor-488 and 
subjected to flow cytometry; A) Representative forward (FSC) and side scatter (SSC) 
diagram of untreated cells used for gating; B) Representative dot plot showing FSC and 
fluorescence of cells treated with 16 µg/ml of chlorpromazine. C) Representative histogram 
showing fluorescence of SH-SY5Y cells treated with indicated chlorpromazine 
concentrations. D) Mean Fluorescence Intensity (MFI) values of anti-CD81 + Alexa-488 
treated with growing concentrations of chlorpromazine (0, 4, 8, 16 and 32 µg/ml), obtained 
as average values of 2 experiments performed either in duplicates or triplicates with the 
total number of samples as quintuplicate (0 and 16 µg/ml), triplicate (4-8 µg/ml) or 
duplicate (32 µg/ml). Standard deviations are depicted as vertical lines. * = statistical 
significance p≤0.05.  
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5. Discussion 
 
The main purpose of this study was to examine whether chlorpromazine 
treatment exerts an effect on the expression of tetraspanin CD81 in human 
neural cells, represented by the neuroblastoma SH-SY5Y and glioblastoma 
U-87 MG cell lines. As already introduced, intercellular communication in 
the CNS relies on the exchange of signals between neurons and glial cells 
through molecular transmitters or via extracellular vesicles. The tetraspanin 
family of proteins is implicated in intercellular contacts (43), while specific 
tetraspanins were associated with neurotransmitter signaling and receptor 
trafficking in neurons (22). CD81 is a tetraspanin known as a marker of 
exosomes, enriched on intercellular membranes (26). In neural cells CD81 
is involved in neuron-astrocyte interactions, astrocyte proliferation and glial 
reactivity (28,30). Chlorpromazine is an antipsychotic drug with multiple 
indications and molecular targets. It acts as an inhibitor of dopamine, 
serotonin, histamine and muscarinic receptors (36). In addition, it blocks 
clathrin-mediated endocytosis and reduces intercellular communication via 
gap junctions in mammalian neurons and astrocytes (32,40). It has been 
associated with a decrease in synapse number accompanied by an increase 
in astrocytic processes (41). These findings directed our attention towards 
exploring the action of chlorpromazine on the tetraspanin CD81 expression 
in human neural cells.  
 
Previous studies indicate that chlorpromazine has a cytotoxic effect in both 
U-87 MG and SH-SY5Y cells. Chlorpromazine showed significant toxicity at 
32 and 320 µg/ml in SH-SY5Y cells, while lower doses did not affect cell 
viability (39). In the present study, as seen in Figure 9B, SH-SY5Y cell 
viability was significantly affected by the highest concentration of 
chlorpromazine that was applied (32 µg/ml), but not with lower doses, 
which is consistent with literature findings. In a separate study, 
chlorpromazine decreased U-87 MG cell viability in a dose-dependent way 
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after 24-hour treatment with 3.2, 6.4 and 12.8 µg/ml of this drug (37). To 
contrast that with our findings, the lowest concentration of chlorpromazine 
used on U-87 MG cells (4 µg/ml) did not cause significant cell death in this 
study (Figure 9A). The reasons for this discrepancy might be in the methods 
used for assessing cell viability. In the present study, a trypan blue dye 
exclusion assay with Neubauer chamber and light microscopy was used to 
visually examine the number of viable cells. This method is simple, 
inexpensive and fast, yet prone to counting errors (44). These errors can 
be attributed to improper filling of the counting chamber, poor cell 
dispersion, cell loss during dispersion, the presence of air bubbles in the 
chamber etc. Furthermore, trypan blue staining does not distinguish 
between healthy cells and ones which are still alive but losing cell functions. 
In the cited study, a commercial kit for WST-8 colorimetric assay was used 
with spectrophotometer measurement of cell viability (37). This assay has 
high reproducibility and avoids the possibility of counting errors (44). Due 
to the difference in obtained data, we propose further testing of 
chlorpromazine effects on U-87 MG cell viability using more sensitive 
methods such as the MTT test or propidium iodide staining and flow 
cytometry analysis. Testing in shorter time intervals might also be 
appropriate.  
 
A flow cytometric analysis of anti-CD81 fluorescence was performed on U-
87MG and SH-SY5Y cells treated with growing concentrations of 
chlorpromazine. The results obtained showed that treatment with 32 µg/ml 
of chlorpromazine led to a significant increase in CD81 expression in U-87 
MG glioblastoma cells (Figure 10D). Lower concentrations of chlorpromazine 
(4, 8 and 16 µg/ml) had no statistically significant effect on CD81 
expression in this cell line. Contrary to this finding, the same drug has led 
to the opposite effect in SH-SY5Y cells, in which treatment with 8 µg/ml of 
chlorpromazine caused significant decrease in CD81 expression compared 
to cells treated with 4 µg/ml (Figure 11D). There was a clear decrease in 
CD81 fluorescence in SH-SY5Y cells treated with 32 µg/ml of 
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chlorpromazine compared to control, but statistical significance was not 
met, probably due to limited number of samples. Nevertheless, there was 
a statistical significance decrease in CD81 fluorescence of SH-SY5Y cells 
treated with 32 µg/ml compared to 4 µg/ml of chlorpromazine. These 
results indicate that chlorpromazine downregulates CD81 in SH-SY5Y cells. 
However, it would be prudent to test these findings on a larger number of 
samples and confirm statistically significant differences between untreated 
controls and other treatment groups. Furthermore, the highest 
concentration applied caused significant cell loss and thus made it difficult 
to appropriately assess the CD81 expression by flow cytometry with the 
initial number of cells that we had. Future experiments with a greater initial 
cell count might provide more conclusive results in SH-SY5Y cells.  
 
Recently, there has been a growing interest for elucidating the non-neuronal 
effects of chlorpromazine. It was found to increase expression levels of 
various proteins associated with the ubiquitination pathway in 
oligodendrocytes (45). CD81 is abundant on multivesicular endosomes or 
multivesicular bodies (MVBs) that can fuse with pre-existing lysosomes and 
thus deliver proteins destined for degradation (46). Our finding that CD81 
is upregulated after 32 µg/ml of chlorpromazine treatment in glioblastoma 
U-87 MG cells also links the actions of this drug with endosomal pathways 
and possibly protein degradation in glial cells. The fact that chlorpromazine 
induces autophagy in U-87 MG cells strengthens this association (37). Other 
possible pathway of MVBs is fusion with the plasma membrane and the 
subsequent release of exosomes into the extracellular space. Knowing that 
CD81 is a recognized marker of exosomes, their intercellular pathways upon 
chlorpromazine treatment might also be affected. It is known that 
chlorpromazine inhibits clathrin-mediated endocytosis of exosomes, but no 
studies have examined its effect on EV biogenesis and secretion. The fact 
that antipsychotics affect cholesterol trafficking might also be associated 
with CD81 changes, considering the role of cholesterol in CD81 
conformations (27,34).  
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In the context of cell-to-cell communication, one study examined the effect 
of chlorpromazine on gap junctions in mouse-derived neuronal cells and rat 
astrocytes (40). This study found a reduction of intercellular communication 
via gap junctions in both cell types following chlorpromazine treatment and 
reversible cellular retraction which reduced cell-cell contacts. A separate 
study described a reduction of the number of synapses in rat hypothalamic 
neurons, accompanied by an increase in astrocytic processes after 
chlorpromazine treatment (41). CD81 was found to be crucial for neuron-
astrocyte interactions and the regulation of astrocyte proliferation (28). 
Changes in CD81 expression due to chlorpromazine treatment might 
participate in cited processes, considering the roles of tetraspanin proteins 
in cell adhesion and proliferation.  
 
Chlorpromazine is a typical antipsychotic drug used not only in the 
treatment of schizophrenia and psychotic disorders, but also as an 
antiemetic, for relief of preoperative anxiety and intraoperative sedation, 
for persistent hiccups and migraines (37). Its main molecular target for 
antipsychotic effects appears to be the dopamine D2 receptor, however it 
acts on other neuronal targets as well. Chlorpromazine was found to block 
voltage sensitive Na+, Ca2+ and K+ ion channels in cells derived from mouse 
neuroblastoma, and it blocks K+ channels in rat sympathetic neurons (part 
of the peripheral nervous system) (40). Due to significant loss of 
neuroblastoma cells after chlorpromazine treatment in our study, it can be 
speculated that neurons are more susceptible to the cytotoxic effects of this 
drug then glial cells, possibly due to the various molecular targets to which 
the drug can bind. Considering the crucial roles of ion channels for signal 
transduction in neurons, the toxicity of chlorpromazine might be interpreted 
through its action on the basic communication processes. CD81 can also be 
implicated via its association with extracellular vesicles, and our data 
suggest it is downregulated by chlorpromazine in neuronal cells.  
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CD81 is a tetraspanin protein involved in cellular proliferation, activation 
and adhesion (27). It was shown to be upregulated in reactive glia upon 
traumatic injury to the CNS (30,47). CD81 was upregulated in reactive 
astrocytes in rat CNS and associated with reactive gliosis and the glial scar 
(48). In our study, chlorpromazine treatment of U-87 MG cells led to an 
increase in CD81 levels at the concentration of 32 µg/ml. In separate 
studies, this drug increased the levels of the anti-inflammatory cytokine 
interleukin (IL)-10 in the supernatant of primary rat mixed glial cell culture 
(49). It inhibited proton currents in microglial BV2 cells, leading the authors 
to speculate that the anti-inflammatory and antipsychotic actions of 
chlorpromazine may be partially due to its inhibition of microglial proton 
channels, which are known to participate in the generation of reactive 
oxygen species (37). Based on the observed cytotoxic effect of 
chlorpromazine on U87-MG cells and the increase of CD81 produced by 
chlorpromazine in these cells in our study, we might speculate that CD81 
upregulation participates in the glial response to injury. 
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6. Conclusion 
 
The results of this study suggest that chlorpromazine exerts different effects 
on cell viability and CD81 protein levels in U-87 MG glioblastoma and to SH-
SY5Y neuroblastoma cell lines. SH-SY5Y are shown to be more sensitive to 
chlorpromazine toxicity in comparison with U-87 MG cells at the 
concentration of 32 µg/ml. Moreover, at this concentration chlorpromazine 
increases CD81 protein levels in U-87 MG cells, while in SH-SY5Y cells it 
leads to a decrease in CD81 expression. These findings provide additional 
information on the mechanisms of chlorpromazine action in neural cells. 
Further studies are required to elucidate whether the observed cellular 
effects are a direct or indirect result of chlorpromazine treatment due to the 
known impairment of endocytosis by chlorpromazine. Since this drug 
upregulates CD81 in U-87 MG cell line, the roles of this protein in glial cell 
activation should be investigated further. Additionally, here described 
opposite effect of chlorpromazine on CD81 protein level in model neuronal 
and glial cells might be relevant for intercellular communication which is 
especially intensive in central nervous system. Namely, CD81 is associated 
with extracellular vesicles known to mediate communication between cells 
including constituents of central nervous system. Future research should 
reveal whether next to intracellular levels, chlorpromazine also affects 
extracellular levels of CD81 protein. This data represents the first step in 
exploring if and how chlorpromazine changes biogenesis and secretion of 
extracellular vesicles in neural cells. 
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